Pull to refresh
Logo
Daily Brief
Following Why Sign Up
The race to replace reading glasses

The race to replace reading glasses

New Capabilities

FDA Approves First Combination Eye Drop, Tenpoint Secures $235M for Launch

January 29th, 2026: FDA Approves YUVEZZI as First Combination Presbyopia Drop

Overview

Updated May 23

For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia.

The approval validates a new therapeutic approach after three earlier presbyopia drops struggled with limited adoption. YUVEZZI combines carbachol and brimonidine to deliver 8-10 hours of near-vision improvement with favorable tolerability—addressing the duration and side effect limitations that hampered Vuity, Qlosi, and Vizz. Tenpoint Therapeutics secured $235 million in financing alongside the approval and plans broad commercial availability in the second quarter of 2026, intensifying competition in a market projected to exceed $20 billion by 2034.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

2 billion
Global presbyopia cases
Number of people worldwide affected by age-related near-vision loss
8-10 hours
Duration of effect
How long YUVEZZI improves near vision after a single dose, compared to 6 hours for Vuity
$235M
Launch financing
Total capital raised through Series B equity ($85M) and credit facility ($150M) to support commercialization
72,000+
Treatment days monitored
BRIO II conducted the longest safety study in presbyopia drop history with no treatment-related serious adverse events

Voices

Curated perspectives — historical figures and your fellow readers.

Benjamin Franklin

Benjamin Franklin

(1706-1790) · Enlightenment · wit

Fictional AI pastiche — not real quote.

"I observe with some amusement that my bifocals, which cost nothing but a bit of glass-grinding ingenuity, have held their ground against the march of progress for two and a half centuries—whilst these modern alchemists now promise to sell drops at no doubt considerable expense to achieve what a penny's worth of curved glass accomplishes admirably. Perhaps in another 240 years, they shall rediscover that the simplest solution to a universal problem need not extract twenty billion dollars from those it serves."

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Henric Bjarke
Henric Bjarke
Chief Executive Officer, Tenpoint Therapeutics
Leading commercial launch preparations following FDA approval
 Ben Bergo
Ben Bergo
President and Chief Business Officer, Tenpoint Therapeutics
Leading commercial preparation for potential launch

Organizations Involved

Tenpoint Therapeutics
Tenpoint Therapeutics
Biotechnology Company
Preparing commercial launch of FDA-approved YUVEZZI in Q2 2026

Global clinical-stage biotech developing treatments for age-related eye conditions including presbyopia, cataracts, and geographic atrophy.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Approved YUVEZZI as fourth presbyopia eye drop

Federal agency responsible for approving new drugs, including presbyopia treatments, for the U.S. market.
AbbVie (Allergan)
AbbVie (Allergan)
Pharmaceutical company
Marketing first-approved presbyopia drop Vuity

Major pharmaceutical company that launched Vuity, the first FDA-approved presbyopia eye drop, in late 2021.
Janus Henderson
Janus Henderson
Publicly Traded Asset Manager
Co-led Tenpoint's $85M Series B financing

Global asset management firm that co-led Tenpoint Therapeutics' Series B financing round in January 2026.
Hercules Capital
Hercules Capital
Specialty Finance Company
Provided $150M credit facility to Tenpoint

Leading specialty financing provider focused on innovative venture capital-backed companies, provided senior secured term loan to Tenpoint.

Timeline

May 1785 January 2026

14 events Latest: January 29th, 2026 · 7 months ago Showing 8 of 14
Tap a bar to jump to that date

  1. FDA Approves YUVEZZI as First Combination Presbyopia Drop

    Latest Regulatory

    FDA approves carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (branded as YUVEZZI, formerly Brimochol PF), the first dual-agent eye drop for presbyopia treatment in adults.

  2. Tenpoint Secures $235 Million in Financing

    Corporate

    Company closes $85 million Series B financing led by Janus Henderson, EQT Nexus, Hillhouse, and British Business Bank, plus $150 million senior secured term loan facility with Hercules Capital to accelerate YUVEZZI commercialization.

  3. FDA Decision Day for Brimochol PF

    Regulatory

    PDUFA target date for FDA to announce approval or rejection of the first combination therapy presbyopia eye drop.

  4. CEO Presents at J.P. Morgan Healthcare Conference

    Corporate

    Henric Bjarke presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting Brimochol PF ahead of the January 28 FDA decision deadline and discussing commercial launch preparations for first half 2026.

  5. FDA Approves Third Presbyopia Drop

    Regulatory

    Vizz (aceclidine 1.44%) becomes the first aceclidine-based presbyopia treatment approved in the U.S., offering up to 10 hours of effect.

  6. FDA Accepts Brimochol PF Application

    Regulatory

    FDA accepts NDA and sets January 28, 2026 as target decision date. Agency indicates no advisory committee meeting will be held.

  7. Tenpoint Submits NDA for Brimochol PF

    Regulatory

    Company files New Drug Application with FDA seeking approval for the first combination presbyopia eye drop.

  8. Qlosi Launches in U.S. Market

    Commercial

    Orasis Pharmaceuticals commercially launches its lower-dose pilocarpine drop after securing funding in late 2024.

  9. BRIO-II Confirms 12-Month Efficacy

    Clinical Trial

    Topline results from the largest presbyopia drop study (629 participants, 70,000+ dosing days) show sustained efficacy with no loss of effect over a year of daily use.

  10. Tenpoint and Visus Therapeutics Merge

    Corporate

    The two clinical-stage biotechs combine to create a focused ophthalmic company, accelerating Brimochol PF toward commercialization.

  11. FDA Approves Second Presbyopia Drop

    Regulatory

    Qlosi (pilocarpine 0.4%) receives FDA approval, offering a lower-concentration alternative to Vuity with fewer reported headaches.

  12. Brimochol PF Hits Phase 3 Endpoints

    Clinical Trial

    BRIO-I pivotal trial demonstrates the carbachol-brimonidine combination outperforms both monotherapy and placebo in improving near vision.

  13. FDA Approves First Presbyopia Eye Drop

    Regulatory

    Vuity (pilocarpine 1.25%) from Allergan/AbbVie becomes the first FDA-approved pharmacological treatment for presbyopia, marking a new therapeutic category.

  14. Benjamin Franklin Invents Bifocals

    Historical

    American inventor describes his bifocal glasses in a letter to George Whatley, establishing the optical solution that would dominate presbyopia treatment for 240 years.

Scenarios

1

FDA Approves Brimochol PF, Fourth Drop Enters Market

Likely

Discussed by: Ophthalmology Times, company investor communications, industry analysts

The FDA grants approval based on strong Phase 3 data showing 8-10 hour duration, 85% response rate, and favorable safety profile. Tenpoint launches in first half of 2026 as planned, positioning the combination therapy as a premium option for patients seeking longer-lasting relief without multiple daily doses. The approval validates the dual-mechanism approach and intensifies competition among presbyopia drop makers.

2

FDA Issues Complete Response, Requests Additional Data

Possible

Discussed by: Pharmaceutical regulatory analysts, industry observers

The FDA declines to approve the application in its current form, requesting additional clinical data or manufacturing documentation. This would delay potential launch by 6-18 months and require Tenpoint to address specific agency concerns. Such outcomes are not uncommon for first-in-class combination products.

3

Approval Granted But Market Adoption Struggles

Possible

Discussed by: Ophthalmology Management, Review of Ophthalmology, prescribing physicians

Brimochol PF wins approval but encounters the same market headwinds that limited Vuity's success: high out-of-pocket costs, insurance coverage gaps, and competition from inexpensive reading glasses. Physicians report improved patient satisfaction compared to earlier drops, but the presbyopia eye drop category remains a fraction of its projected potential.

4

Brimochol PF Becomes Category Leader, Reshapes Market

Possible

Discussed by: Healthcare equity analysts, ophthalmology conference presentations

The combination drop's superior duration and tolerability profile drives rapid market share gains against Vuity, Qlosi, and Vizz. Strong physician recommendations and word-of-mouth lead to broader acceptance of pharmacological presbyopia treatment. Tenpoint's success attracts acquisition interest from major pharmaceutical companies seeking ophthalmology pipeline assets.

5

YUVEZZI Overcomes Market Headwinds, Drives Category Growth

Possible

Discussed by: Ophthalmology Management, industry analysts

The combination therapy's superior 8-10 hour duration and improved tolerability profile address the specific limitations that hampered Vuity adoption. If Tenpoint prices competitively and secures favorable insurance coverage, the $235 million in financing provides runway to invest in physician education and direct-to-consumer marketing. Strong early adoption could validate the pharmacological presbyopia treatment category and expand the total addressable market beyond early adopters.

6

Price Premium Limits Market to Affluent Early Adopters

Possible

Discussed by: Healthcare market analysts, payer organizations

YUVEZZI launches at a price point above Vuity's $79 monthly cost, positioning as a premium option justified by longer duration and combination mechanism. Without broad insurance coverage, the market remains constrained to affluent patients and former LASIK recipients willing to pay out-of-pocket for vision freedom. The $235 million financing sustains operations but the presbyopia drop category continues to underperform projections.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1999-2010

LASIK's Transformation of Refractive Surgery (1999-2010)

Laser-assisted in-situ keratomileusis (LASIK) went from experimental procedure to mainstream vision correction, with millions of Americans choosing surgery over glasses or contact lenses. The procedure's adoption accelerated as technology improved, prices dropped, and patient testimonials spread.

Then

LASIK became a $2+ billion annual market in the U.S. by the mid-2000s, fundamentally changing how refractive errors were treated.

Now

A generation of LASIK patients now entering presbyopia age have perfect distance vision but still need reading glasses. These patients are considered ideal candidates for presbyopia drops—they've already embraced technology-based vision solutions and have higher disposable income.

Why this matters now

Presbyopia drop companies specifically target former LASIK patients, who represent motivated customers accustomed to investing in vision freedom. If combination drops like Brimochol PF prove effective, this demographic could drive adoption in ways that early drops haven't achieved.

October 2021 - December 2022

Vuity Launch and Market Reality Check (2021-2022)

AbbVie's Allergan launched Vuity as the first FDA-approved presbyopia eye drop with massive consumer awareness campaigns. Initial enthusiasm was high—128 million Americans theoretically represented the target market. Ophthalmologist Steven Dell called the launch "masterful" with unprecedented category awareness.

Then

Prescriptions peaked early then declined as patients encountered headaches, 6-hour duration limits, and the $79 monthly cost not covered by insurance.

Now

The experience taught the industry that efficacy alone isn't sufficient—duration, tolerability, and price all matter for patient adoption. Subsequent drops (Qlosi, Vizz) were designed to address Vuity's specific limitations.

Why this matters now

Brimochol PF's clinical development explicitly targeted Vuity's weaknesses: the combination therapy offers 8-10 hour duration versus 6, brimonidine reduces the redness side effect common to miotics, and the preservative-free formulation improves tolerability. The real test is whether these improvements translate to better commercial performance.

Sources

(20)
+14
Ophthalmology Times Business Wire Ophthalmology Management AbbVie News GoodRx Cataract & Refractive Surgery Today Presbyopia Physician BioSpace Ophthalmology Advisor MedCity News FiercePharma Endpoints News Modern Optometry Ophthalmology Times Business Wire Ophthalmology Times BioSpace Business Wire Ophthalmology Management Ophthalmology Advisor